Pritesh Shah Insider Trading $NVCR NovoCure Ltd
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Pritesh Shah.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Pritesh Shah. Pritesh Shah is Chief Commercial Officer in NovoCure Ltd ($NVCR).
Pritesh Shah in NovoCure Ltd
Industry: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
Position of Pritesh Shah: Chief Commercial Officer
Holdings: 101,272 shares
Current Value: $688,650
Latest Transaction: May 06 2021
$NVCR Market Capitalization: $581.43M
$NVCR Previous Close: $6.80
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of Pritesh Shah in NovoCure Ltd
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 06 2021 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 199.67 | 1,290 | 257,574 | 101,272 | 102.6 K to 101.3 K (-1.26 %) |
| Mar 10 2021 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 131.09 | 3,524 | 461,961 | 101,272 | 104.8 K to 101.3 K (-3.36 %) |
| Mar 10 2021 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 130.81 | 2,627 | 343,627 | 104,796 | 107.4 K to 104.8 K (-2.45 %) |
| Mar 09 2021 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Option Exercise | M | 7.15 | 13,987 | 100,007 | 0 | |
| Mar 09 2021 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 131.53 | 4,550 | 598,462 | 107,423 | 112 K to 107.4 K (-4.06 %) |
| Mar 09 2021 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Buy | M | 7.15 | 13,987 | 100,007 | 111,973 | 98 K to 112 K (+14.27 %) |
| Mar 05 2021 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 137.55 | 2,658 | 365,619 | 97,986 | 100.6 K to 98 K (-2.64 %) |
| Mar 05 2021 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 150.78 | 2,174 | 327,796 | 100,644 | 102.8 K to 100.6 K (-2.11 %) |
| Mar 04 2021 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Option Exercise | A | 153.09 | 20,004 | 3,062,412 | 20,004 | |
| Mar 04 2021 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Grant | A | 0.00 | 10,886 | 0 | 102,818 | 91.9 K to 102.8 K (+11.84 %) |
| Mar 04 2021 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 152.05 | 912 | 138,672 | 91,932 | 92.8 K to 91.9 K (-0.98 %) |
| Mar 02 2021 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Option Exercise | M | 0.00 | 3,086 | 0 | 0 | |
| Mar 02 2021 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Buy | M | 149.10 | 3,086 | 460,123 | 92,844 | 89.8 K to 92.8 K (+3.44 %) |
| Sep 11 2020 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 86.07 | 700 | 60,252 | 70,465 | 71.2 K to 70.5 K (-0.98 %) |
| Sep 11 2020 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 85.39 | 27,621 | 2,358,629 | 71,165 | 98.8 K to 71.2 K (-27.96 %) |
| Sep 03 2020 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Option Exercise | A | 84.68 | 3,779 | 320,006 | 3,779 | |
| Sep 03 2020 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | P | 85.01 | 4,200 | 357,054 | 98,786 | 103 K to 98.8 K (-4.08 %) |
| Sep 03 2020 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Grant | A | 0.00 | 1,968 | 0 | 102,986 | 101 K to 103 K (+1.95 %) |
| Aug 05 2020 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 76.81 | 2,048 | 157,307 | 101,018 | 103.1 K to 101 K (-1.99 %) |
| Aug 05 2020 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 76.41 | 1,669 | 127,522 | 103,066 | 104.7 K to 103.1 K (-1.59 %) |
| Aug 03 2020 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Option Exercise | M | 0.00 | 3,717 | 0 | 3,717 | |
| Aug 03 2020 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Buy | M | 76.17 | 3,717 | 283,124 | 104,735 | 101 K to 104.7 K (+3.68 %) |
| Jul 08 2020 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Grant | A | 50.41 | 325 | 16,382 | 101,018 | 100.7 K to 101 K (+0.32 %) |
| May 07 2020 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 62.20 | 1,149 | 71,468 | 100,693 | 101.8 K to 100.7 K (-1.13 %) |
| May 07 2020 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 62.20 | 1,149 | 71,468 | 100,693 | 101.8 K to 100.7 K (-1.13 %) |
| May 05 2020 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Option Exercise | M | 0.00 | 2,333 | 0 | 2,333 | |
| May 05 2020 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 60.08 | 1,184 | 71,134 | 101,842 | 103 K to 101.8 K (-1.15 %) |
| May 05 2020 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Buy | M | 65.80 | 2,333 | 153,511 | 103,026 | 100.7 K to 103 K (+2.32 %) |
| Mar 10 2020 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Option Exercise | M | 7.48 | 17,500 | 130,900 | 14,518 | |
| Mar 10 2020 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 64.27 | 3,245 | 208,556 | 100,693 | 103.9 K to 100.7 K (-3.12 %) |
| Mar 10 2020 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Buy | M | 7.48 | 17,500 | 130,900 | 103,938 | 86.4 K to 103.9 K (+20.25 %) |
| Mar 10 2020 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 69.53 | 2,906 | 202,066 | 86,438 | 89.3 K to 86.4 K (-3.25 %) |
| Mar 05 2020 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Option Exercise | A | 69.37 | 41,690 | 2,892,035 | 41,690 | |
| Mar 05 2020 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Grant | A | 0.00 | 21,623 | 0 | 89,344 | 67.7 K to 89.3 K (+31.93 %) |
| Mar 05 2020 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 72.97 | 1,485 | 108,360 | 67,721 | 69.2 K to 67.7 K (-2.15 %) |
| Mar 02 2020 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Option Exercise | M | 0.00 | 3,086 | 0 | 3,086 | |
| Mar 02 2020 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 72.22 | 1,601 | 115,616 | 69,206 | 70.8 K to 69.2 K (-2.26 %) |
| Mar 02 2020 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Buy | M | 79.45 | 3,086 | 245,183 | 70,807 | 67.7 K to 70.8 K (+4.56 %) |
| Feb 26 2020 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Option Exercise | M | 0.00 | 12,999 | 0 | 0 | |
| Feb 26 2020 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Buy | M | 88.26 | 12,999 | 1,147,292 | 80,720 | 67.7 K to 80.7 K (+19.19 %) |
| Oct 28 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Option Exercise | M | 7.48 | 4,580 | 34,258 | 32,018 | |
| Oct 28 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Buy | M | 7.48 | 4,580 | 34,258 | 67,721 | 63.1 K to 67.7 K (+7.25 %) |
| Aug 26 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | J | 97.80 | 13,835 | 1,353,063 | 63,141 | 77 K to 63.1 K (-17.97 %) |
| Aug 06 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 85.23 | 1,813 | 154,522 | 76,976 | 78.8 K to 77 K (-2.30 %) |
| Aug 02 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Option Exercise | M | 0.00 | 3,718 | 0 | 7,434 | |
| Aug 02 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Option Exercise | M | 34.00 | 5,115 | 173,910 | 15,343 | |
| Aug 02 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 83.20 | 1,905 | 158,502 | 78,789 | 80.7 K to 78.8 K (-2.36 %) |
| Aug 02 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Buy | M | 83.30 | 3,718 | 309,709 | 80,694 | 77 K to 80.7 K (+4.83 %) |
| Aug 02 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 82.92 | 5,115 | 424,136 | 76,976 | 82.1 K to 77 K (-6.23 %) |
| Aug 02 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Buy | M | 34.00 | 5,115 | 173,910 | 82,091 | 77 K to 82.1 K (+6.64 %) |
| Jul 30 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Option Exercise | M | 19.25 | 12,500 | 240,625 | 25,000 | |
| Jul 30 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 80.06 | 100 | 8,006 | 76,976 | 77.1 K to 77 K (-0.13 %) |
| Jul 30 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 79.41 | 3,857 | 306,288 | 77,076 | 80.9 K to 77.1 K (-4.77 %) |
| Jul 30 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 78.68 | 2,455 | 193,150 | 80,933 | 83.4 K to 80.9 K (-2.94 %) |
| Jul 30 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 77.28 | 2,800 | 216,376 | 83,388 | 86.2 K to 83.4 K (-3.25 %) |
| Jul 30 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 76.39 | 2,710 | 207,017 | 86,188 | 88.9 K to 86.2 K (-3.05 %) |
| Jul 30 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 75.04 | 578 | 43,372 | 88,898 | 89.5 K to 88.9 K (-0.65 %) |
| Jul 30 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Buy | M | 19.25 | 12,500 | 240,625 | 89,476 | 77 K to 89.5 K (+16.24 %) |
| Jul 22 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Option Exercise | M | 27.60 | 7,500 | 207,000 | 22,500 | |
| Jul 22 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 70.00 | 7,500 | 525,000 | 76,976 | 84.5 K to 77 K (-8.88 %) |
| Jul 22 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Buy | M | 27.60 | 7,500 | 207,000 | 84,476 | 77 K to 84.5 K (+9.74 %) |
| Jul 22 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Option Exercise | M | 27.60 | 7,500 | 207,000 | 22,500 | |
| Jul 22 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 70.00 | 7,500 | 525,000 | 76,976 | 84.5 K to 77 K (-8.88 %) |
| Jul 22 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Buy | M | 27.60 | 7,500 | 207,000 | 84,476 | 77 K to 84.5 K (+9.74 %) |
| Jul 09 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Grant | A | 27.81 | 764 | 21,248 | 76,976 | 76.2 K to 77 K (+1.00 %) |
| Jun 28 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 60.30 | 11,175 | 673,853 | 65,037 | 76.2 K to 65 K (-14.66 %) |
| Jun 21 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Option Exercise | M | 11.85 | 12,500 | 148,125 | 25,000 | |
| Jun 21 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 60.00 | 12,500 | 750,000 | 76,212 | 88.7 K to 76.2 K (-14.09 %) |
| Jun 21 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Buy | M | 11.85 | 12,500 | 148,125 | 88,712 | 76.2 K to 88.7 K (+16.40 %) |
| Jun 12 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 55.60 | 60 | 3,336 | 76,212 | 76.3 K to 76.2 K (-0.08 %) |
| Jun 12 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 55.02 | 1,070 | 58,876 | 76,272 | 77.3 K to 76.3 K (-1.38 %) |
| May 10 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Option Exercise | A | 47.56 | 20,000 | 951,200 | 20,000 | |
| May 10 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Option Exercise | A | 47.56 | 33,052 | 1,571,953 | 33,052 | |
| Apr 01 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Option Exercise | M | 7.03 | 8,869 | 62,349 | 0 | |
| Apr 01 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Option Exercise | M | 6.72 | 23,652 | 158,941 | 0 | |
| Apr 01 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Buy | M | 7.03 | 8,869 | 62,349 | 76,212 | 67.3 K to 76.2 K (+13.17 %) |
| Apr 01 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Buy | M | 6.72 | 23,652 | 158,941 | 67,343 | 43.7 K to 67.3 K (+54.13 %) |
| Mar 26 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Option Exercise | A | 47.04 | 33,783 | 1,589,152 | 33,783 | |
| Mar 26 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Grant | A | 0.00 | 18,452 | 0 | 43,691 | 25.2 K to 43.7 K (+73.11 %) |
| Mar 04 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Option Exercise | M | 21.15 | 16,897 | 357,372 | 45,961 | |
| Mar 04 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Option Exercise | M | 7.15 | 16,250 | 116,188 | 18,514 | |
| Mar 04 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Option Exercise | M | 11.46 | 7,439 | 85,251 | 24 | |
| Mar 04 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 56.09 | 7,736 | 433,943 | 25,239 | 33 K to 25.2 K (-23.46 %) |
| Mar 04 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 55.23 | 9,161 | 505,990 | 32,975 | 42.1 K to 33 K (-21.74 %) |
| Mar 04 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Buy | M | 21.15 | 16,897 | 357,372 | 42,136 | 25.2 K to 42.1 K (+66.95 %) |
| Mar 04 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 56.10 | 7,517 | 421,681 | 25,239 | 32.8 K to 25.2 K (-22.95 %) |
| Mar 04 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 55.23 | 8,733 | 482,297 | 32,756 | 41.5 K to 32.8 K (-21.05 %) |
| Mar 04 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Buy | M | 7.15 | 16,250 | 116,188 | 41,489 | 25.2 K to 41.5 K (+64.38 %) |
| Mar 04 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 56.11 | 3,312 | 185,840 | 25,239 | 28.6 K to 25.2 K (-11.60 %) |
| Mar 04 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 55.23 | 4,127 | 227,947 | 28,551 | 32.7 K to 28.6 K (-12.63 %) |
| Mar 04 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Buy | M | 11.46 | 7,439 | 85,251 | 32,678 | 25.2 K to 32.7 K (+29.47 %) |
| Jan 18 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Option Exercise | M | 19.25 | 12,500 | 240,625 | 37,500 | |
| Jan 18 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Option Exercise | M | 11.85 | 12,500 | 148,125 | 37,500 | |
| Jan 18 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 45.00 | 12,500 | 562,538 | 17,087 | 29.6 K to 17.1 K (-42.25 %) |
| Jan 18 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Buy | M | 19.25 | 12,500 | 240,625 | 29,587 | 17.1 K to 29.6 K (+73.16 %) |
| Jan 18 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 45.00 | 12,500 | 562,538 | 17,087 | 29.6 K to 17.1 K (-42.25 %) |
| Jan 18 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Buy | M | 11.85 | 12,500 | 148,125 | 29,587 | 17.1 K to 29.6 K (+73.16 %) |
| Jan 14 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Option Exercise | M | 11.46 | 17,500 | 200,550 | 7,463 | |
| Jan 14 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Option Exercise | M | 14.37 | 8,751 | 125,752 | 0 | |
| Jan 14 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 42.00 | 17,500 | 735,070 | 17,087 | 34.6 K to 17.1 K (-50.60 %) |
| Jan 14 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Buy | M | 11.46 | 17,500 | 200,550 | 34,587 | 17.1 K to 34.6 K (+102.42 %) |
| Jan 14 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 42.00 | 8,751 | 367,577 | 17,087 | 25.8 K to 17.1 K (-33.87 %) |
| Jan 14 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Buy | M | 14.37 | 8,751 | 125,752 | 25,838 | 17.1 K to 25.8 K (+51.21 %) |
| Jan 11 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Option Exercise | M | 14.37 | 8,988 | 129,158 | 8,751 | |
| Jan 11 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 40.01 | 3,023 | 120,950 | 17,087 | 20.1 K to 17.1 K (-15.03 %) |
| Jan 11 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 40.00 | 5,965 | 238,600 | 20,110 | 26.1 K to 20.1 K (-22.88 %) |
| Jan 11 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Buy | M | 14.37 | 8,988 | 129,158 | 26,075 | 17.1 K to 26.1 K (+52.60 %) |
| Dec 13 2018 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Option Exercise | M | 7.15 | 16,249 | 116,180 | 34,764 | |
| Dec 13 2018 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Option Exercise | M | 7.48 | 22,532 | 168,539 | 0 | |
| Dec 13 2018 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 36.01 | 830 | 29,888 | 17,087 | 17.9 K to 17.1 K (-4.63 %) |
| Dec 13 2018 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 36.00 | 15,419 | 555,084 | 17,917 | 33.3 K to 17.9 K (-46.25 %) |
| Dec 13 2018 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Buy | M | 7.15 | 16,249 | 116,180 | 33,336 | 17.1 K to 33.3 K (+95.10 %) |
| Dec 13 2018 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 36.01 | 1,150 | 41,412 | 17,087 | 18.2 K to 17.1 K (-6.31 %) |
| Dec 13 2018 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 36.00 | 21,382 | 769,752 | 18,237 | 39.6 K to 18.2 K (-53.97 %) |
| Dec 13 2018 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Buy | M | 7.48 | 22,532 | 168,539 | 39,619 | 17.1 K to 39.6 K (+131.87 %) |
| Aug 02 2018 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Option Exercise | A | 0.00 | 11,152 | 0 | 11,152 | |
| Aug 02 2018 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Option Exercise | A | 34.00 | 20,458 | 695,572 | 20,458 | |
| Jul 10 2018 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Grant | A | 17.26 | 1,231 | 21,241 | 5,231 | 4 K to 5.2 K (+30.78 %) |
Page: 1